
Durable treatments impact the quality of life of patients with retinal diseases.

The diagnostic and monitoring tools use artificial intelligence-based models.

The adaptor was tested by low-vision patients and participants with simulated visual impairment.

Physicians wonder whether normal examination results are actually normal.

Peter McDonnell, MD, shares his thoughts on Omar R. Shakir's, MD, MBA, article on office-based vitrectomy surgery.

The multi-institutional found that a genetic variation common in people of African ancestry is linked with an increased risk of complications from diabetes, including diabetic retinopathy, which has previously been linked to genetic variations called single nucleotide polymorphisms, or SNPs, but these associations have been studied primarily in individuals of European and Asian ancestry.

Enhanced monofocal technology may benefit patients with cataracts and dry eye.

The 2024 event was held in Seattle, Washington, from May 5 through May 9. Members of the Ophthalmology Times team attended and interviewed several researchers and industry professionals, highlighting news from the meeting.

The adaptor was tested by low-vision patients and participants with simulated visual impairment

According to the company, its combined vitreoretinal-cataract system and standalone cataract system are cleared for use in the United States.

Researchers at Washington University School of Medicine in St. Louis for years have worked to understand the rare condition known as retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations.

The results were presented at a symposium during the American Diabetes Association's 84th Scientific Sessions in Orlando, Florida, and mark the first large-scale trial specifically designed to investigate the effect of fenofibrate on eye outcomes in people with early diabetic retinopathy.

According to the company, the acquisition includes 2 commercial assets Iluvien and Yutiq, expanding ANI’s foothold in ophthalmology.

Phase 1 multicenter study demonstrates early signs of efficacy.

Researchers at Washington University School of Medicine in St. Louis for years have worked to understand the rare condition known as retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations.

The introduction of red/green/blue (RGB) color is a welcome addition to ultrawidefield imaging that will aid in the screening and detection of retinal diseases.

A team of Korean researchers has examined data from the Korean National Health Information Database to determine whether subjects with allergic diseases exhibited a higher incidence of primary open-angle glaucoma compared to a control group.

Technology brings new tools to those with low vision caused by AMD

Ophthalmologists graded AI bots' answers to questions from patients following cataract surgery

OCU410ST is a modifier gene therapy candidate being developed for Stargardt disease, which affects approximately 100,000 people in the United States and Europe combined.


Optimizing corneal neurotization outcomes with cryopreserved amniotic membrane.

How retina specialists are approaching treatment of GA in clinic.

The US Food and Drug Administration issued designations for the allogeneic cell therapy candidate, a therapeutic for corneal oedema

The second and third required PPQ batches are scheduled, and should they meet specifications, the new TRIESENCE production process will be complete, allowing Harrow to relaunch during 2024.

A priority review has been granted with a PDUFA goal date set for December 17, 2024.

According to the company, AURN001 is the first allogeneic cell therapy to receive both FDA designations for the treatment of corneal edema secondary to corneal endothelial disease.

Researchers found that blocking the interaction between peptide and receptor using topical applications of naltrexone reverses dry eye symptoms in 5 days and restores tear fluid volumes to normal baseline.


Anat Loewenstein, MD, spoke with Modern Retina about her presentation of AXPAXLI trial results and upcoming trials for this potential treatment, which she gave at Clinical Trials at the Summit meeting held in Park City, Utah on June 8, 2024.